4D Molecular receives FDA RMAT designation for 4D-150

4D Molecular Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted the Regenerative Medicine Advanced Therapy, RMAT, designation for the investigational genetic medicine candidate 4D-150 for intravitreal treatment of wet age-related macular degeneration. The FDA granted RMAT designation based on the potential of 4D-150 to address the unmet medical need within this population. “We are honored to receive the first ever RMAT designation for an investigational treatment for wet AMD with our intravitreal 4D-150 genetic medicine,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. “This designation validates our belief in 4D-150’s potential to address the high unmet need of wet AMD patients, to maintain their visual acuity outcomes, and to reduce their treatment burden. We continue to work closely with the FDA and EMA on efficiently advancing 4D-150 development for both wet AMD and diabetic macular edema, and having both RMAT and PRIME designations enables us to further collaborate expeditiously in our efforts to advance development in both geographies.”